Full Press Release Details
Absci Reports Third Quarter 2021 Financial and Operating Results
VANCOUVER, Wash. November 9, 2021 - Absci Corporation (Nasdaq ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today reported financial and operating results for the quarter ended September 30, 2021.
"At Absci, our team of Unlimiters is building technology to enable better, faster, smarter biologic drug and target discovery and cell line development," said Sean McClain, founder and CEO. "2021 continues to be a transformative year for our organization, with the business experiencing tremendous momentum, highlighted by strategic acquisitions and partnerships, important additions to the team in key roles, and our debut as a public company - all on top of the scientific innovation we do each and every day. We continue to have success in integrating our recent acquisitions, and we are already generating exciting opportunities from our expanded platform, including signing our first major multi-program discovery deal last month."
Third Quarter 2021 and Recent Highlights
Hired additional experienced employees, including vital areas of data science, artificial intelligence, intellectual property, and research and development. Absci's team now includes nearly 220 Unlimiters.
Continued integrating our acquisitions, further developing AI-enabled discovery capabilities and beginning to capitalize on drug discovery opportunities enabled through Absci's expanded platform.
Announced a partnership with EQRx to discover and develop next-generation protein-based drugs. The partnership will leverage Absci's Drug Creation technology for discovery and development activities, along with EQRx's clinical development expertise and commercial capabilities, to advance next-generation, protein-based therapeutics at more affordable costs for patients. EQRx and Absci will collaborate to jointly engineer and develop several clinical candidates across multiple therapeutic areas, including oncology and immunology.
Third Quarter 2021 Financial Results
Revenue was $1.5 million for the three months ended September 30, 2021 compared to $0.9 million for the three months ended September 30, 2020.
Research and development expenses were $10.7 million for the third quarter of 2021, as compared to $2.7 million for the corresponding prior year period. This increase was primarily driven by additional investments in platform expansion, including data initiatives and AI capabilities.
Selling, general, and administrative expenses were $9.7 million for the third quarter of 2021, as compared to $1.3 million for the corresponding prior year period. This increase was primarily due to personnel-related costs and other expenses related to being a publicly traded company.
Net loss was $23.6 million for the third quarter of 2021, as compared to $3.7 million for the corresponding prior year period, which includes a non-cash charge of $3.6 million related to the revaluation of convertible notes and preferred stock warrants.
Cash and cash equivalents were $279.3 million as of September 30, 2021. On July 26, 2021, Absci completed its initial public offering, raising approximately $210 million of net proceeds, after deducting underwriting discounts and commissions and offering expenses.
Absci will host a conference call to discuss the third quarter 2021 financial results before market open on Tuesday, November 9, 2021 at 5 30 a.m. Pacific Time 8 30 a.m. Eastern Time. A webcast of the conference call can be accessed at http investors.absci.com. The webcast will be archived and available for replay for at least 90 days after the event.
Availability of Other Information about Absci
Investors and others should note that we routinely communicate with investors and the public using our website (www.absci.com) and the "Investors" section of our website (investors.absci.com), including without limitation, through the posting of investor presentations, SEC filings, press releases, public conference calls and webcasts on these websites. The information that we post on these websites could be deemed to be material information. As a result, investors, the media, and others interested in Absci are encouraged to review this information on a regular basis. The contents of our website, or any other website that may be accessed from our website, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Forward-Looking Statements
Certain statements in this press release that are not historical facts are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements containing the words "will," "pursues," "anticipates," "plans," "believes," "forecast," "estimates," "expects," and "intends," or similar expressions. We intend these forward-looking statements, including statements regarding technology development efforts, integrating acquisitions and partnerships, expanding our platform, scientific innovation efforts, drug discovery and development activities, potential costs of therapeutics, and clinical candidate development, to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, and we make this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies, and prospects, which are based on the information currently available to us and on assumptions we have made. We can give no assurance that the plans, intentions, expectations, or strategies will be attained or achieved, and, furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control, including, without limitation, risks and uncertainties relating to our ability to effectively collaborate on drug discovery and development activities with our partners along with those risks set forth in our most recent periodic report filed with the U.S. Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the U.S. Securities and Exchange Commission. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise.
Condensed Consolidated Statements of Operations (unaudited)
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||||||||||||||
| (In thousands, except for share and per share data) | 2021 | 2020 | 2021 | 2020 | ||||||||||||
| Revenues | ||||||||||||||||
| Technology development revenue | $ | 1,390 | $ | 922 | $ | 2,922 | $ | 1,964 | ||||||||
| Collaboration revenue | 149 | (6) | 408 | 88 | ||||||||||||
| Total revenues | 1,539 | 916 | 3,330 | 2,052 | ||||||||||||
| Operating expenses | ||||||||||||||||
| Research and development | 10,730 | 2,692 | 28,820 | 6,851 | ||||||||||||
| Selling, general and administrative | 9,733 | 1,257 | 19,597 | 3,089 | ||||||||||||
| Depreciation and amortization | 2,218 | 331 | 3,895 | 780 | ||||||||||||
| Total operating expenses | 22,681 | 4,280 | 52,312 | 10,720 | ||||||||||||
| Operating loss | (21,142) | (3,364) | (48,982) | (8,668) | ||||||||||||
| Other income (expense) | ||||||||||||||||
| Interest expense | (768) | (172) | (3,232) | (459) | ||||||||||||
| Other income (expense), net | (3,427) | (212) | (31,377) | (287) | ||||||||||||
| Total other expense, net | (4,195) | (384) | (34,609) | (746) | ||||||||||||
| Loss before income taxes | (25,337) | (3,748) | (83,591) | (9,414) | ||||||||||||
| Income tax benefit | 1,703 | - | 7,797 | - | ||||||||||||
| Net loss | (23,634) | (3,748) | (75,794) | (9,414) | ||||||||||||
| Adjustment of redeemable preferred units and stock | - | (9,215) | - | (34,336) | ||||||||||||
| Cumulative undeclared preferred stock dividends | (242) | - | (2,284) | - | ||||||||||||
| Net loss applicable to common stockholders and unitholders | $ | (23,876) | $ | (12,963) | $ | (78,078) | $ | (43,750) | ||||||||
| Net loss per share attributable to common stockholders and unitholders Basic and diluted | $ | (0.33) | $ | (0.85) | $ | (2.16) | $ | (2.88) | ||||||||
| Weighted-average common shares and units outstanding Basic and diluted | 73,291,288 | 15,215,747 | 36,177,105 | 15,215,747 |
Condensed Consolidated Balance Sheets (unaudited)
| September 30, | December 31, | |||||||
| (In thousands, except for share and per share data) | 2021 | 2020 | ||||||
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 279,262 | $ | 69,867 | ||||
| Restricted cash | 10,512 | - | ||||||
| Receivables under development arrangements | 714 | 1,594 | ||||||
| Prepaid expenses and other current assets | 10,177 | 1,773 | ||||||
| Total current assets | 300,665 | 73,234 | ||||||
| Operating lease right-of-use assets | 7,378 | 4,476 | ||||||
| Property and equipment, net | 44,090 | 8,909 | ||||||
| Intangibles, net | 55,835 | - | ||||||
| Goodwill | 23,013 | - | ||||||
| Restricted cash, long-term | 16,843 | 1,841 | ||||||
| Other long-term assets | 1,295 | 109 | ||||||
| TOTAL ASSETS | $ | 449,119 | $ | 88,569 | ||||
| LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND OTHER STOCKHOLDERS' DEFICIT | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 6,372 | $ | 2,116 | ||||
| Accrued expenses | 15,275 | 1,569 | ||||||
| Loans payable | - | 632 | ||||||
| Long-term debt, current | 2,400 | 903 | ||||||
| Operating lease obligations, current | 1,461 | 770 | ||||||
| Financing lease obligations, current | 2,772 | 1,475 | ||||||
| Deferred revenue, current | 1,968 | 2,630 | ||||||
| Total current liabilities | 30,248 | 10,095 | ||||||
| Convertible promissory notes | - | - | ||||||
| Long-term debt - net of current portion | 1,712 | 4,141 | ||||||
| Operating lease obligations - net of current portion | 9,362 | 3,813 | ||||||
| Finance lease obligations - net of current portion | 4,008 | 2,766 | ||||||
| Deferred tax, net | 3,525 | - | ||||||
| Deferred revenue | 122 | - | ||||||
| Other long-term liabilities | 12,129 | 749 | ||||||
| TOTAL LIABILITIES | 61,106 | 21,564 | ||||||
| Commitments | ||||||||
| Redeemable convertible preferred stock, $0.0001 par value | - | 156,433 | ||||||
| OTHER STOCKHOLDERS' DEFICIT | ||||||||
| Preferred stock, $0.0001 par value | - | - | ||||||
| Common stock, $0.0001 par value | 9 | 2 | ||||||
| Additional paid-in capital | 553,878 | 635 | ||||||
| Accumulated deficit | (165,859) | (90,065) | ||||||
| Accumulated other comprehensive loss | (15) | - | ||||||
| TOTAL OTHER STOCKHOLDERS' DEFICIT | 388,013 | (89,428) | ||||||
| TOTAL LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND OTHER STOCKHOLDERS' DEFICIT | $ | 449,119 | $ | 88,569 |